Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2408094 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review.
Heart Fail Rev
December 2024
Division of Cardiovascular Medicine, University of Virginia, 1215 Lee St Box 800158, Charlottesville, VA, 22908, USA.
Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by left ventricular, non-dilated hypertrophy in the absence of another secondary underlying cause. There has been an ongoing increase in the diagnosis of HCM over the past couple of decades, prompting further work in the area of pharmacological and interventional therapies. This scoping review aimed to summarize the traditional therapeutic options for HCM and to explore emerging research on novel cardiac myosin inhibitors (CMIs) as a new option for pharmacologic management of HCM.
View Article and Find Full Text PDFCardiac Myosin Inhibitors for Obstructive Hypertrophic Cardiomyopathy: A Meta-analysis of Randomized Placebo-Controlled Trials.
Am J Cardiovasc Drugs
December 2024
Department of Medicine, Cardiology, Baylor College of Medicine, Houston, TX, USA.
Background: Cardiac myosin inhibitors (CMI) have emerged as the first disease-specific, noninvasive therapy with promising results in patients with hypertrophic cardiomyopathy. However, its role in obstructive hypertrophic cardiomyopathy (oHCM) remains uncertain, especially in secondary endpoints of randomized controlled trials (RCTs).
Methods: We systematically searched PubMed, Embase, Web of Science, and Clinicaltrials.
Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond.
Egypt Heart J
December 2024
Baqai Medical University, 51, Deh Tor, Gadap Road, Near Toll Plaza, SuperHighway,, P.O. Box 2407, Karachi, 75340, Sindh, Pakistan.
Background: A cardiac condition marked by excessive growth of heart muscle cells, hypertrophic cardiomyopathy (HCM) is a complex genetic disorder characterized by left ventricular hypertrophy, microvascular ischemia, myocardial fibrosis, and diastolic dysfunction. Obstructive hypertrophic cardiomyopathy (oHCM), a subset of HCM, involves significant obstruction in the left ventricular outflow tract (LVOT), leading to symptoms like dyspnea, fatigue, and potentially life-threatening cardiac events. With advancements in genetic understanding and the introduction of novel pharmacologic agents, including cardiac myosin inhibitors like mavacamten and aficamten, there is a paradigm shift in the therapeutic approach to oHCM.
View Article and Find Full Text PDFAficamten Versus Placebo in Patients With Hypertrophic Obstructive Cardiomyopathy: A Systematic Review and Meta-Analysis.
Am J Ther
November 2024
Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Cardiac Myosin Inhibition in Obstructive Hypertrophic Cardiomyopathy: Can Aficamten Stand Alone?
J Am Coll Cardiol
November 2024
Division of Cardiology, Cardiovascular and Thoracic Department, Città della Salute e della Scienza, Turin, Italy; Department of Medical Sciences, University of Turin, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!